Lexaria Bioscience
LEXX
20 hedge funds and large institutions have $1.05M invested in Lexaria Bioscience in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0.08% less ownership
Funds ownership: 0.59% → 0.51% (-0.08%)
17% less funds holding
Funds holding: 24 → 20 (-4)
36% less capital invested
Capital invested by funds: $1.63M → $1.05M (-$582K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$335K |
| 2 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
+$70.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$42.5K |
| 4 |
Renaissance Technologies
New York
|
+$5.21K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$185 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$400K |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$29.9K |
| 3 |
VF
Virtu Financial
New York
|
-$28K |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$5.95K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Rockefeller Capital Management
New York
| – | -$191 | -13 | Closed |
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$6 | – | – |
|
LEXX Hedge Fund Activity: Q4 2025 in Review
20 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2025, worth a combined $1.05M — down 36% from $1.63M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LEXX and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was UBS Group, adding an estimated $335K. The largest seller was Murchinson, exiting entirely with an estimated $400K sold.
- 20 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2025, down from 24 in Q3 2025.
- Funds reported $1.05M of Lexaria Bioscience stock for Q4 2025, down 36% quarter-over-quarter.
- 1 fund opened new Lexaria Bioscience positions in Q4 2025 and 5 closed out, a net change of -4 holders.
- The largest Lexaria Bioscience buyer in Q4 2025 was UBS Group, an estimated $335K added.
- The largest Lexaria Bioscience seller in Q4 2025 was Murchinson, an estimated $400K sold.
Based on aggregated 13F filings for Q4 2025.